The objective of the meeting was to learn more about common fields of interests and what possibilities there are for collaboration between the two organisations.
Sanofi Aventis has a long and proud history within neuroscience, which began with the introduction of the phenotiazines for psychosis and schizophrenia as well as tricyclic antidepressants long time ago that was a revolution in psychiatry. Since then the company has introduces numerous medicines in the field of neuroscience, and is still active in R&D as well as on the search of new opportunities in the field. In this connection the company met with Nansen Neuroscience Network together with the members, Smartfish, Optinose and CMBN (Centre for Molecular Biology and Neuroscience).
The meeting was the first formal interaction between the organizations and there was a useful exchange of information about what Sanofi Aventis will be looking for among collaborators. Both Smartfish and Optinose presented technology and scientific data that Sanofi Aventis appeared to find interesting and deserved a closer look in order to evaluate the possibilities for collaboration. CMBN was also presented in brief, by Linda Bergersen, but it was clear that a more detailed presentation of the opportunities that exist within the vast CMBN organisation should be planned for.
On a final note it should be concluded that already now at a very early stage of the organisation Nansen Neuroscience Network and its members have expertise and technology that can attract the interest of the leading international healthcare companies for potential collaboration.
No comments:
Post a Comment